Patents Examined by Yunsoo Kim
  • Ophthalmic drug delivery system containing phospholipid and cholesterol
    Patent number: 10660960
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: May 26, 2020
    Assignees: TAIWAN LIPOSOME CO., LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
  • Pharmaceutical formulations
    Patent number: 10653781
    Abstract: A stable pharmaceutical formulation is provided that comprises a biologically active protein and an excipient selected from carnitine, creatine or creatinine.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: May 19, 2020
    Assignee: AMGEN INC.
    Inventors: Christopher James Sloey, Camille Gleason, Jason Ko, Tiansheng Li
  • Formulations with reduced oxidation
    Patent number: 10653779
    Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 19, 2020
    Assignee: GENENTECH, INC.
    Inventors: Sreedhara Alavattam, Mary Mallaney, Parbir Grewal
  • High concentration protein formulations with reduced viscosity
    Patent number: 10646569
    Abstract: The present disclosure, among other things, provides low-viscosity, high concentration therapeutic protein agent formulations.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: May 12, 2020
    Assignee: Bhami's Research Laboratory, Pvt. Ltd.
    Inventor: Bhami Shenoy
  • Liquid protein formulations containing cimetidine
    Patent number: 10646571
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 12, 2020
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Methods for inducing an immune response
    Patent number: 10624961
    Abstract: Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition, wherein a lower dose is given in the second administration than in the first administration, and wherein the second administration may be unadjuvanted.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: April 21, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: William Ripley Ballou, Jr., Arnaud Michel Didierlaurent, Robbert Gerrit Van Der Most
  • Phosphoserine containing compositions for immune tolerance induction
    Patent number: 10617640
    Abstract: Compositions and methods for inducing immune tolerance to proteins and subsequence administration of the proteins are disclosed. Compositions comprise proteins complexed with liposomes comprising PS and PC, wherein at least part of the PS is present as lyso-PS.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: April 14, 2020
    Assignee: The Research Foundation for The State University of New York
    Inventors: Sathy Balu-Iyer, Richard Bankert, Radha Ramakrishnan, Robert Dingman, Vandana Iyer, Jennifer Schneider, Fiona Yau Glassman, Nhan Hanh Nguyen
  • Immunoglobulin purification
    Patent number: 10590186
    Abstract: The current invention reports a method for purifying an immunoglobulin, wherein the method comprises applying an aqueous, buffered solution comprising an immunoglobulin in monomeric and in aggregated form to a cation exchange material under conditions whereby the immunoglobulin in monomeric form does not bind to the cation exchange material, and recovering the immunoglobulin in monomeric form from the solution after the contact with the cation exchange material.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: March 17, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Roberto Falkenstein, Claudia Giessel
  • Antibody-nanoparticle conjugates for the treatment of drug abuse
    Patent number: 10550201
    Abstract: The present invention generally relates to an antibody composition including antibodies conjugated to nanoparticles. The antibody composition may be used in methods to treat drug use, drug addiction, and effects of drug use.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 4, 2020
    Assignee: BioVentures, LLC
    Inventors: Eric C. Peterson, Nisha Nanaware-Kharade, Guillermo Gonzalez, III
  • Low concentration antibody formulations
    Patent number: 10537638
    Abstract: The present invention is directed formulations for low concentrations of therapeutic proteins and methods of making the same. In one aspect the present invention is directed to a formulation for a therapeutic protein comprising: a) the therapeutic protein; and b) a surfactant; wherein the molar ratio of surfactant to therapeutic protein is at least 100. In another aspect the present invention is directed to a formulation for a therapeutic protein comprising: a) the therapeutic protein; and b) an antioxidant, wherein the molar ratio of antioxidant to therapeutic protein is at least 750.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 21, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: George Crotts, Sorina Morar-Mitrica
  • Polyvalent immunotherapeutics
    Patent number: 10538577
    Abstract: The invention is related to the production and development of a lyophilized injectable formulation of modified antibodies or their variants, highly specific neutralizers of heterologous mixtures of proteins, peptides and other organic or inorganic components have different specific activities and may include but are not limited to the venoms of venomous animals. For convenience, we refer to venoms, but all type of venoms was included of land and marine animals. It is also addressed to the production method which includes the hyperimmunization of mammals for the production of highly specific antibodies, the modification (fragmentation) and purification process, and finally the injectable formulation conferring thereon properties of high purity and high specificity.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: January 21, 2020
    Assignee: INOSAN BIOPHARMA S.A.
    Inventors: Juan Lopez De Silanes Perez, Jesús Raúl Soria Osorio
  • Stabilized aqueous antibody compositions
    Patent number: 10532098
    Abstract: The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/mL and an oligomer of ethyleneimine, wherein the number of repeating units of ethyleneimine (n) in the oligomer is in the range n=2-12.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: January 14, 2020
    Assignee: Arecor Limited
    Inventors: Jan Jezek, Guy Casy, Barry Kingston Derham, Nikki Royle
  • Stable IGG4 based binding agent formulations
    Patent number: 10525130
    Abstract: The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: January 7, 2020
    Assignee: Sanofi
    Inventors: Julia Schnieders, Dirk Usener, Sabrina Ruggeberg, Ahmed Youssef, Martina Kirsch, Annika Hagendorf
  • Antibody formulations and methods
    Patent number: 10513555
    Abstract: The invention provides antibody formulations and methods useful for prophylaxis or treatment of synucleinopathies, including Parkinson's disease.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 24, 2019
    Assignee: Prothena Biosciences Limited
    Inventors: Patrick Garidel, Andreas Langer, Michael Grundman
  • Carbohydrate content of CTLA4 molecules
    Patent number: 10508144
    Abstract: The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: December 17, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kirk J. Leister, Eugene J. Schaefer, Ronald Charles Bates, Elizabeth A. Bramhall, David Michael Didio, Robert Donaldson, Alan R. Flesher, Helen Gray Haggerty, David Henry Kirkley, John Malcolm Tabor, Lee K. Tay, Pallaiah Thammana, Ajoy Velayudhan, David Edward Smolin, Reb J. Russell, Thomas James Vanden Boom, Dean Woodrow Brownell, Jeffrey Schrimsher, Joyce Patricia Whitehead
  • Polymers for delivery of therapeutic proteins
    Patent number: 10500256
    Abstract: In some aspects, improved hydrogel copolymers (e.g., comprising itaconic acid and N-vinylpyrrolidone) are provided and may be used, e.g., for oral delivery of a therapeutic protein. In some embodiments, improved methods for loading a therapeutic protein (e.g., a high isoelectric point protein) into a hydrogel copolymer are provided, and may comprise incubating the therapeutic protein and the hydrogel in a reduced ionic strength loading solution. In some embodiments, use of the reduced ionic strength loading solution can result in hydrogel copolymer-therapeutic protein compositions that display improved pharmacokinetic attributes, e.g., improved loading and/or release of a therapeutic protein.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: December 10, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Michael Koetting, Nicholas Peppas
  • Immune response inducer
    Patent number: 10493137
    Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: December 3, 2019
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Masaki Ishibashi, Fumiyoshi Okano
  • Immune response inducer
    Patent number: 10493138
    Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: December 3, 2019
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Masaki Ishibashi, Fumiyoshi Okano
  • Immune response inducer
    Patent number: 10493136
    Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: December 3, 2019
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Masaki Ishibashi, Fumiyoshi Okano
  • Excipient compounds for biopolymer formulations
    Patent number: 10478498
    Abstract: The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid protein formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions. The inventive methods can also yield a higher stability of a liquid protein formulation.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: November 19, 2019
    Assignee: REFORM BIOLOGICS, LLC
    Inventors: David S. Soane, Philip Wuthrich, Rosa Casado Portilla, Robert P. Mahoney, Mark Moody, Daniel G. Greene